Utility of hepatic phosphorus-31 magnetic resonance spectroscopy in a rat model of acute liver failure

Journal of Investigative Medicine

Volumn 51, Issue 1, 2003, Pages 42-49

  Corbin, Ian R ^a   Buist, Richard ^a   Peeling, Jim ^a   Zhang, Manna ^c   Uhanova, Julia ^a   Minuk, Gerald Y ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b John Buhler Research Centre   (Canada)

^c NONE

Author keywords

31P magnetic resonance spectroscopy; Adenosine triphosphate; D galactosamine; Hepatocyte mass; Liver; Liver failure; Liver function; Liver necrosis; Metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GALACTOSAMINE; PHOSPHORUS 31;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER TRANSPLANTATION; METABOLITE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROGNOSIS; RAT; RAT STRAIN; TREATMENT INDICATION;

ANIMALIA;

EID: 0037291738     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2003.33540     Document Type: Article

References (58)

1. O'Grady JG, Williams R. Classification of acute liver failure. Lancet 1993;342:743.
2. Bernstein D, Tripodi J. Fulminant hepatic failure. Crit Care Clin 1998;14:181-97.
3. Lee WM. Acute liver failure. N Engl J Med 1993;329:1862-72.
4. Bismuth H, Samuel D, Gugenheim J, et al. Emergency liver transplantation for fulminant hepatitis. Ann Intern Med 1987;107:337-41.
5. Peleman RR, Gavaler JS, Van Thiel DH, et al. Orthotopic liver transplantation for acute and subacute hepatic failure in adults. Hepatology 1987;7:484-9.
6. Brems JJ, Hiatt JR, Ramming KP, et al. Fulminant hepatic failure: the role of liver transplantation as primary therapy. Am J Surg 1987;154:137-41.
7. Levinsky NG. Organ donation by unrelated donors. N Engl J Med 2000;343:430-2.
8. Keeffe EB. Patient selection and listing policies for liver transplantation. J Gastroenterol Hepatol 1999;14 Suppl:S42-7.
9. Carraro P, Burighel D, De Silvestro G, et al. Early prognostic biochemical indicators of fulminant hepatic failure. Int J Clin Lab Res 1998;28:196-9.
10. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
11. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician 1999;59:2223-30.
12. Donaldson BW, Gopinath R, Wanless IR, et al. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology 1993;18:1370-6.
13. Scotto J, Opolon P, Eteve J, et al. Liver biopsy and prognosis in acute liver failure. Gut 1973;14:927-33.
14. Tygstrup N, Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis 1986;6:129-37.
15. Sekiyama K, Yoshiba M, Inoue K, Sugata F. Prognostic value of hepatic volumetry in fulminant hepatic failure. Dig Dis Sci 1994;39:240-4.
16. Deasy NP, Wendon J, Meire HB, Sidhu PS. The value of serial Doppler ultrasound as a predictor of clinical outcome and the need for transplantation in fulminant and severe acute liver failure. Br J Radiol 1999;72:134-43.
17. Schneeweiss B, Pammer J, Ratheiser K, et al. Energy metabolism in acute hepatic failure. Gastroenterology 1993;105:1515-21.
18. Rosser BG, Gores GJ. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology 1995;108:252-75.
19. Terblanche J, Hickman R. Animal models of fulminant hepatic failure. Dig Dis Sci 1991;36:770-4.
20. Muntane J, Rodriguez FJ, Segado O, et al. TNF-alpha dependent production of inducible nitric oxide is involved in PGE (1) protection against acute liver injury. Gut 2000;47:553-62.
21. Keppler D, Lesch R, Reutter W, Decker K. Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol 1968;9:279-90.
22. Meyerhoff DJ, Karczmar GS, Matson GB, et al. Non-invasive quantitation of human liver metabolites using image-guided 31P magnetic resonance spectroscopy. NMR Biomed 1990;3:17-22.
23. Roth K, Hubesch B, Meyerhoff D, et al. Non-invasive quantitation of phosphorus metabolites in human tissue by NMR spectroscopy. J Magn Reson B 1989;81:299-310.
24. Evelhoch JL, Ewy CS, Siegfried BA, et al. 31P spin-lattice relaxation times and resonance linewidths of rat tissue in vivo: dependence upon the static magnetic field strength. Magn Reson Med 1985;2:410-7.
25. Iles RA, Stevens AN, Griffiths JR, Morris PG. Phosphorylation status of liver by 31P-n.m.r. spectroscopy, and its implications for metabolic control. A comparison of 31P-n.m.r. spectroscopy (in vivo and in vitro) with chemical and enzymic determinations of ATP, ADP and Pi. Biochem J 1985;229:141-51.
26. Brennan RJ, Mankes RF, Lefevre R, et al. 4-Methylpyrazole blocks acetaminophen hepatotoxicity in the rat. Ann Emerg Med 1994;23:487-94.
27. Koff RS, Connelly LJ. Modification of the hepatotoxicity of D-galactosamine in the rat by cycloheximide. Proc Soc Exp Biol Med 1976;151:519-22.
28. Kono T, Kotani H, Asama T, et al. Protective effect of pretreatment with low-dose lipopolysaccharide on D-galactosamine-induced acute liver failure. Int J Colorectal Dis 2002;17:98-103.
29. Kalpana K, Ong HS, Soo KC, et al. An improved model of galactosamine-induced fulminant hepatic failure in the pig. J Surg Res 1999;82:121-30.
30. Shito M, Balis UJ, Tompkins RG, et al. A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha. Dig Dis Sci 2001;46:1700-8.
31. Bates TE, Williams SR, Busza AL, et al. A 31P nuclear magnetic resonance study in vivo of metabolic abnormalities in rats with acute liver failure. NMR Biomed 1988;1:67-73.
32. Chen B, Burt CT, Goering PL, et al. In vivo 31P nuclear magnetic resonance studies of arsenite induced changes in hepatic phosphate levels. Biochem Biophys Res Commun 1986;139:228-34.
33. Locke SJ, Brauer M. The response of the rat liver in situ to bromobenzene - in vivo proton magnetic resonance imaging and 31P magnetic resonance spectroscopy studies. Toxicol Appl Pharmacol 1991;110:416-28.
34. Munakata T, Tanaka K, Mito M. 31P nuclear magnetic resonance study of intrahepatic energy metabolism in acute liver failure. Nippon Geka Gakkai Zasshi 1990;91:77-85.
35. Ramsoe K, Andreasen PB, Ranek L. Functioning liver mass in uncomplicated and fulminant acute hepatitis. Scand J Gastroenterol 1980;15:65-72.
36. Milandri M, Gaub J, Ranek L. Evidence for liver cell proliferation during fatal acute liver failure. Gut 1980;21:423-7.
37. Koukoulis G, Rayner A, Tan KC, et al. Immunolocalization of regenerating cells after submassive liver necrosis using PCNA staining. J Pathol 1992;166:359-68.
38. Bucher NL. Regeneration of mammalian liver. In: International review of cytology. New York: Academic Press; 1963. p. 245-300.
39. Corbin I, Buist RJ, Peeling J, et al. Examination of regenerative activity and liver function following partial hepatectomy in the rat utilizing hepatic phosphorus-31 magnetic resonance spectroscopy. Hepatology 2002;36:345-53.
40. Keppler D, Decker K. Studies on the mechanism of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 1969;10:219-25.
41. Keppler DO, Rudigier JF, Bischoff E, Decker KF. The trapping of uridine phosphates by D-galactosamine, D-glucosamine, and 2-deoxy-D-galactose. A study on the mechanism of galactosamine hepatitis. Eur J Biochem 1970;17:246-53.
42. Mourelle M, Meza MA. Colchicine prevents D-galactosamine-induced hepatitis. J Hepatol 1989;8:165-72.
43. Schuz-Henninger R, Prinz C, Decker K. Ganglioside biosynthesis in rat liver: effect of UDP-amino sugars on individual transfer reactions. Arch Biochem Biophys 1988;262:49-58.
44. Decker K, Keppler D, Pausch J. The regulation of pyrimidine nucleotide level and its role in experimental hepatitis. Adv Enzyme Regul 1973;11:205-30.
45. Sabesin SM, Koff RS. D-Galactosamine hepatotoxicity. IV. Further studies of the pathogenesis of fatty liver. Exp Mol Pathol 1976;24:424-34.
46. Bell JD, Cox IJ, Sargentoni J, et al. A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Biochim Biophys Acta 1993;1225:71-7.
47. Perlman ME, Davis DG, Gabel SA, London RE. Uridine diphospho sugars and related hexose phosphates in the liver of hexosamine-treated rats: identification using 31P-[1H] two-dimensional NMR with HOHAHA relay. Biochemistry 1990;29:4318-25.
48. Weisdorf S, Hendrich K, Buchthal S, et al. Hepatic D-galactosamine toxicity studied with localized in vivo 31P magnetic resonance spectroscopy in intact rats. Magn Reson Med 1991;21:178-90.
49. Morikawa S, Inubushi T, Kitoh K, et al. Chemical assessment of phospholipid and phosphoenergetic metabolites in regenerating rat liver measured by in vivo and in vitro 31P-NMR. Biochim Biophys Acta 1992;1117:251-7.
50. Murphy EJ, Brindle KM, Rorison CJ, et al. Changes in phosphatidylethanolamine metabolism in regenerating rat liver as measured by 31P-NMR. Biochim Biophys Acta 1992;1135:27-34.
51. Taylor-Robinson SD, Sargentoni J, Bell JD, et al. In vivo and in vitro hepatic 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver 1997;17:198-209.
52. Taylor-Robinson SD, Thomas EL, Sargentoni J, et al. Cirrhosis of the human liver: an in vitro 31P nuclear magnetic resonance study. Biochim Biophys Acta 1995;1272:113-8.
53. Menon DK, Sargentoni J, Taylor-Robinson SD, et al. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology 1995;21:417-27.
54. Thomas CP, Dixon RM, Tian M, et al. Phosphorus metabolism during growth of lymphoma in mouse liver: a comparison of 31P magnetic resonance spectroscopy in vivo and in vitro. Br J Cancer 1994;69:633-40.
55. Dixon RM, Tian M. Phospholipid synthesis in the lymphomatous mouse liver studied by 31P nuclear magnetic resonance spectroscopy in vitro and by administration of 14C-radiolabelled compounds in vivo. Biochim Biophys Acta 1993;1181:111-21.
56. Taylor-Robinson SD, Sargentoni J, Bell JD, et al. In vivo and in vitro hepatic phosphorus-31 magnetic resonance spectroscopy and electron microscopy in chronic ductopenic rejection of human liver allografts. Gut 1998;42:735-43.
57. Gazzard BG, Portmann B, Murray-Lyon IM, Williams R. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. QJM 1975;44:615-26.
58. Van Thiel DH, Brems J, Nadir A, et al. Liver transplantation for fulminant hepatic failure. J Gastroenterol 2001;36:1-4.